The MEC1 and MEC2 lines represent two CLL subclones in different stages of progression towards prolymphocytic leukemia

Eahsan Rasul, D. Salamon, Noemi Nagy, Benjamin Leveau, Ferenc Banati, Kalman Szenthe, Anita Koroknai, J. Mináróvits, George Klein, Eva Klein

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The EBV carrying lines MEC1 and MEC2 were established earlier from explants of blood derived cells of a chronic lymphocytic leukemia (CLL) patient at different stages of progression to prolymphocytoid transformation (PLL). This pair of lines is unique in several respects. Their common clonal origin was proven by the rearrangement of the immunoglobulin genes. The cells were driven to proliferation in vitro by the same indigenous EBV strain. They are phenotypically different and represent subsequent subclones emerging in the CLL population. Furthermore they reflect the clinical progression of the disease. We emphasize that the support for the expression of the EBV encoded growth program is an important differentiation marker of the CLL cells of origin that was shared by the two subclones. It can be surmised that proliferation of EBV carrying cells in vitro, but not in vivo, reflects the efficient surveillance that functions even in the severe leukemic condition. The MEC1 line arose before the aggressive clinical stage from an EBV carrying cell within the subclone that was in the early prolymphocytic transformation stage while the MEC2 line originated one year later, from the subsequent subclone with overt PLL characteristics. At this time the disease was disseminated and the blood lymphocyte count was considerably elevated. The EBV induced proliferation of the MEC cells belonging to the subclones with markers of PLL agrees with earlier reports in which cells of PLL disease were infected in vitro and immortalized to LCL. They prove also that the expression of EBV encoded set of proteins can be determined at the event of infection. This pair of lines is particularly important as they provide in vitro cells that represent the subclonal evolution of the CLL disease. Furthermore, the phenotype of the MEC1 cells shares several characteristics of ex vivo CLL cells.

Original languageEnglish
Article numbere106008
JournalPLoS One
Volume9
Issue number8
DOIs
Publication statusPublished - Aug 27 2014

Fingerprint

Prolymphocytic Leukemia
lymphocytic leukemia
B-Cell Chronic Lymphocytic Leukemia
Phase locked loops
leukemia
Human Herpesvirus 4
Blood
cells
Lymphocytes
Differentiation Antigens
Immunoglobulins
Genes
Immunoglobulin Genes
immunoglobulin genes
Lymphocyte Count
lymphocyte count
blood
Disease Progression
Blood Cells
Proteins

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

The MEC1 and MEC2 lines represent two CLL subclones in different stages of progression towards prolymphocytic leukemia. / Rasul, Eahsan; Salamon, D.; Nagy, Noemi; Leveau, Benjamin; Banati, Ferenc; Szenthe, Kalman; Koroknai, Anita; Mináróvits, J.; Klein, George; Klein, Eva.

In: PLoS One, Vol. 9, No. 8, e106008, 27.08.2014.

Research output: Contribution to journalArticle

Rasul, Eahsan ; Salamon, D. ; Nagy, Noemi ; Leveau, Benjamin ; Banati, Ferenc ; Szenthe, Kalman ; Koroknai, Anita ; Mináróvits, J. ; Klein, George ; Klein, Eva. / The MEC1 and MEC2 lines represent two CLL subclones in different stages of progression towards prolymphocytic leukemia. In: PLoS One. 2014 ; Vol. 9, No. 8.
@article{908f635656c445a48b917b534ae2c692,
title = "The MEC1 and MEC2 lines represent two CLL subclones in different stages of progression towards prolymphocytic leukemia",
abstract = "The EBV carrying lines MEC1 and MEC2 were established earlier from explants of blood derived cells of a chronic lymphocytic leukemia (CLL) patient at different stages of progression to prolymphocytoid transformation (PLL). This pair of lines is unique in several respects. Their common clonal origin was proven by the rearrangement of the immunoglobulin genes. The cells were driven to proliferation in vitro by the same indigenous EBV strain. They are phenotypically different and represent subsequent subclones emerging in the CLL population. Furthermore they reflect the clinical progression of the disease. We emphasize that the support for the expression of the EBV encoded growth program is an important differentiation marker of the CLL cells of origin that was shared by the two subclones. It can be surmised that proliferation of EBV carrying cells in vitro, but not in vivo, reflects the efficient surveillance that functions even in the severe leukemic condition. The MEC1 line arose before the aggressive clinical stage from an EBV carrying cell within the subclone that was in the early prolymphocytic transformation stage while the MEC2 line originated one year later, from the subsequent subclone with overt PLL characteristics. At this time the disease was disseminated and the blood lymphocyte count was considerably elevated. The EBV induced proliferation of the MEC cells belonging to the subclones with markers of PLL agrees with earlier reports in which cells of PLL disease were infected in vitro and immortalized to LCL. They prove also that the expression of EBV encoded set of proteins can be determined at the event of infection. This pair of lines is particularly important as they provide in vitro cells that represent the subclonal evolution of the CLL disease. Furthermore, the phenotype of the MEC1 cells shares several characteristics of ex vivo CLL cells.",
author = "Eahsan Rasul and D. Salamon and Noemi Nagy and Benjamin Leveau and Ferenc Banati and Kalman Szenthe and Anita Koroknai and J. Min{\'a}r{\'o}vits and George Klein and Eva Klein",
year = "2014",
month = "8",
day = "27",
doi = "10.1371/journal.pone.0106008",
language = "English",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

TY - JOUR

T1 - The MEC1 and MEC2 lines represent two CLL subclones in different stages of progression towards prolymphocytic leukemia

AU - Rasul, Eahsan

AU - Salamon, D.

AU - Nagy, Noemi

AU - Leveau, Benjamin

AU - Banati, Ferenc

AU - Szenthe, Kalman

AU - Koroknai, Anita

AU - Mináróvits, J.

AU - Klein, George

AU - Klein, Eva

PY - 2014/8/27

Y1 - 2014/8/27

N2 - The EBV carrying lines MEC1 and MEC2 were established earlier from explants of blood derived cells of a chronic lymphocytic leukemia (CLL) patient at different stages of progression to prolymphocytoid transformation (PLL). This pair of lines is unique in several respects. Their common clonal origin was proven by the rearrangement of the immunoglobulin genes. The cells were driven to proliferation in vitro by the same indigenous EBV strain. They are phenotypically different and represent subsequent subclones emerging in the CLL population. Furthermore they reflect the clinical progression of the disease. We emphasize that the support for the expression of the EBV encoded growth program is an important differentiation marker of the CLL cells of origin that was shared by the two subclones. It can be surmised that proliferation of EBV carrying cells in vitro, but not in vivo, reflects the efficient surveillance that functions even in the severe leukemic condition. The MEC1 line arose before the aggressive clinical stage from an EBV carrying cell within the subclone that was in the early prolymphocytic transformation stage while the MEC2 line originated one year later, from the subsequent subclone with overt PLL characteristics. At this time the disease was disseminated and the blood lymphocyte count was considerably elevated. The EBV induced proliferation of the MEC cells belonging to the subclones with markers of PLL agrees with earlier reports in which cells of PLL disease were infected in vitro and immortalized to LCL. They prove also that the expression of EBV encoded set of proteins can be determined at the event of infection. This pair of lines is particularly important as they provide in vitro cells that represent the subclonal evolution of the CLL disease. Furthermore, the phenotype of the MEC1 cells shares several characteristics of ex vivo CLL cells.

AB - The EBV carrying lines MEC1 and MEC2 were established earlier from explants of blood derived cells of a chronic lymphocytic leukemia (CLL) patient at different stages of progression to prolymphocytoid transformation (PLL). This pair of lines is unique in several respects. Their common clonal origin was proven by the rearrangement of the immunoglobulin genes. The cells were driven to proliferation in vitro by the same indigenous EBV strain. They are phenotypically different and represent subsequent subclones emerging in the CLL population. Furthermore they reflect the clinical progression of the disease. We emphasize that the support for the expression of the EBV encoded growth program is an important differentiation marker of the CLL cells of origin that was shared by the two subclones. It can be surmised that proliferation of EBV carrying cells in vitro, but not in vivo, reflects the efficient surveillance that functions even in the severe leukemic condition. The MEC1 line arose before the aggressive clinical stage from an EBV carrying cell within the subclone that was in the early prolymphocytic transformation stage while the MEC2 line originated one year later, from the subsequent subclone with overt PLL characteristics. At this time the disease was disseminated and the blood lymphocyte count was considerably elevated. The EBV induced proliferation of the MEC cells belonging to the subclones with markers of PLL agrees with earlier reports in which cells of PLL disease were infected in vitro and immortalized to LCL. They prove also that the expression of EBV encoded set of proteins can be determined at the event of infection. This pair of lines is particularly important as they provide in vitro cells that represent the subclonal evolution of the CLL disease. Furthermore, the phenotype of the MEC1 cells shares several characteristics of ex vivo CLL cells.

UR - http://www.scopus.com/inward/record.url?scp=84938407676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938407676&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0106008

DO - 10.1371/journal.pone.0106008

M3 - Article

C2 - 25162594

AN - SCOPUS:84938407676

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 8

M1 - e106008

ER -